Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,027 | -3,858 | -2,262 | -1,036 | -11,508 |
| Depreciation Amortization | 157 | 118 | 78 | 46 | 206 |
| Other Working Capital | 23 | 57 | 76 | 23 | 134 |
| Other Operating Activity | 1,665 | 113 | -299 | -326 | 3,767 |
| Operating Cash Flow | $-5,183 | $-3,571 | $-2,407 | $-1,293 | $-7,401 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,017 | -17 | -17 | -17 | -13 |
| Investing Cash Flow | $-3,017 | $-17 | $-17 | $-17 | $-13 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | N/A | -29 |
| Common Stock Issued | 5,733 | 1,153 | 1,003 | 146 | 7,837 |
| Financing Cash Flow | $5,733 | $1,153 | $1,003 | $146 | $7,809 |
| Beginning Cash Position | 3,230 | 3,230 | 3,230 | 3,230 | 2,834 |
| End Cash Position | 762 | 794 | 1,809 | 2,065 | 3,230 |
| Net Cash Flow | $-2,467 | $-2,435 | $-1,421 | $-1,165 | $396 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,183 | -3,571 | -2,407 | -1,293 | -7,401 |
| Capital Expenditure | -3,017 | -17 | -17 | -17 | -16 |
| Free Cash Flow | -8,200 | -3,588 | -2,424 | -1,310 | -7,417 |